JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN)- Therapeutic Core

项目摘要-治疗核心 HIV感染者存在多种中枢神经系统合并症，因此有必要采取更全面的方法 推进新的艾滋病毒神经疗法。为了应对这些挑战，JHU进步中心 HIV神经治疗学(JHU Cahn)将发展成为一个全方位的综合研究中心 与PWH相关的中枢神经系统并发症。治疗核心的主要目标是作为一个 专门的药物发现单位，并通过与其他JHU Cahn密切合作来开发新的疗法 以及联系神经艾滋病毒领域内外的研究人员，包括那些 隶属于其他NIMH神经艾滋病毒中心和工业部门。这一雄心勃勃的目标将通过 一名经验丰富的药物研发人员监督在治疗机构内建立的四个关键职能 核心，即药物化学、分析开发/筛选、药物代谢和药代动力学， 和动物药理学/毒理学。与药物发现相关的集体资源将用于 参与神经艾滋病毒翻译研究的调查人员，重点是早期调查人员，在- 代表少数族裔和艾滋病毒新手的调查人员。为药物量身定做的多学科结构 发现研究还允许核心提供广泛的药物发现培训和教育 机会(例如，实习、研究金、毕业后和研究生培训、药物发现和 翻译课程)。此外，治疗核心是独特的定位，以促进对 利用CORE广泛的网络，在行业中出现与艾滋病毒相关的CNS并发症 多年来通过多个学术-生物制药合作伙伴关系建立起来的。与各中心密切合作 生物标记物、临床和开发核心，治疗核心准备通过 落实以下三个具体目标：(目标1)建立药物研发平台 治疗PWH中枢神经系统并发症的新疗法；(目标2)评价目标1中的药物疗效 HIV感染小鼠模型的神经行为表型研究(目标3)提供药物发现教育 以及对学术界的服务。参与生物制药公司研究艾滋病毒的新疗法 合并症。

PROJECT SUMMARY – THERAPEUTIC CORE The multiple CNS comorbidities present in HIV-infected individuals necessitate a more holistic approach in advancing new HIV neurotherapeutics. In line with these challenges, the JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN) will evolve into a comprehensive research center targeting all aspects of CNS complications associated with PWH. The main objective of the Therapeutic Core is to serve as a dedicated drug discovery unit and to develop new therapeutics by working closely with other JHU CAHN cores as well as reaching out to investigators both in and outside the field of NeuroHIV including those affiliated with other NIMH NeuroHIV centers and the industrial sector. This ambitious goal will be enabled by a highly experienced drug discovery staff overseeing four key functions established within the Therapeutic Core, namely, medicinal chemistry, assay development/screening, drug metabolism and pharmacokinetics, and animal pharmacology/toxicology. The collective drug discovery-related resources will be directed toward investigators involved in NeuroHIV translational research, with a focus on early-stage investigators, under- represented minorities, and investigators new to HIV. The multidisciplinary structure tailored to drug discovery research also allows the core to provide a wide range of drug discovery training and educational opportunities (e.g., internships, fellowships, post-baccalaureate and graduate training, drug discovery and translational courses). Furthermore, the Therapeutic Core is uniquely positioned to promote awareness of HIV-related CNS complications among the industry sector by taking advantage of core’s extensive network built over years through multiple academic-biopharma partnerships. Working closely with the centers’ Biomarker, Clinical, and Developmental cores, the Therapeutic Core is poised to seize this opportunity by executing the following three Specific Aims: (Objective 1) Establish a drug discovery platform to develop novel therapeutics for CNS complications in PWH; (Objective 2) Evaluate drugs from Objective 1 for effect on neurobehavioral phenotypes in murine models of HIV; (Objective 3) Provide drug discovery education and services to the academic community. Engage with biopharma to investigate novel therapeutics for HIV comorbidities.